Numab Therapeutics has raised approximately $110m (CHF100m) through Series C funding to expedite the clinical development of its multi-specific antibody pipeline in oncology and inflammation.
Swiss biotech Numab has raised CHF22m ($22.7m) in a Series B financing round, which attracted multiple new investors from Asia, including 3SBio, Mitsubishi UFJ Capital and Eisai, as well as a company board member Dr Daniel Vasella.